Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ARROWHEAD PHARMACEUTICALS, INC.

(ARWR)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/11/2021 10/12/2021 10/13/2021 10/14/2021 10/15/2021 Date
60.1(c) 63.27(c) 63.37(c) 66.83(c) 66.16(c) Last
347 952 533 264 369 776 540 091 559 772 Volume
-0.38% +5.27% +0.16% +5.46% -1.00% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 174 M - -
Net income 2021 -68,2 M - -
Net cash position 2021 296 M - -
P/E ratio 2021 -112x
Yield 2021 -
Sales 2022 241 M - -
Net income 2022 -14,5 M - -
Net cash position 2022 377 M - -
P/E ratio 2022 -199x
Yield 2022 -
Capitalization 6 898 M 6 898 M -
EV / Sales 2021 38,0x
EV / Sales 2022 27,1x
Nbr of Employees 232
Free-Float 96,5%
More Financials
Company
Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company uses a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company's therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. The Company is focused on developing drugs for diseases with a genetic basis,... 
More about the company
Ratings of Arrowhead Pharmaceuticals, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
D+
More Ratings
All news about ARROWHEAD PHARMACEUTICALS, INC.
10/12ARROWHEAD PHARMACEUTICALS : to Host Key Opinion Leader Webinar on ARO-C3 for Treatment of ..
BU
09/30ARROWHEAD PHARMACEUTICALS : Begins Phase 2b Study of Drug Candidate for Mixed Dyslipidemia
MT
09/30ARROWHEAD PHARMACEUTICALS : Initiates Phase 2b Study of ARO-APOC3 for Treatment of Mixed D..
BU
09/30Arrowhead Pharmaceuticals, Inc. Initiates Phase 2b Study of ARO-APOC3 for Treatment of ..
CI
09/29ARROWHEAD PHARMACEUTICALS : to Participate in Upcoming October 2021 Conferences
BU
09/28ARROWHEAD PHARMACEUTICALS : Earns $10 Million Phase 1 Milestone Payment, Based on Agreemen..
MT
09/28ARROWHEAD PHARMACEUTICALS : Earns $10 Million Phase 1 Milestone Payment
BU
09/28Arrowhead Pharmaceuticals, Inc. Earns $10 Million Phase 1 Milestone Payment
CI
09/14INSIDER SELL : Arrowhead Pharmaceuticals
MT
09/10INSIDER SELL : Arrowhead Pharmaceuticals
MT
09/01ARROWHEAD PHARMACEUTICALS : to Participate in Upcoming September 2021 Conferences
BU
08/27ARROWHEAD PHARMACEUTICALS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
08/27James Hassard, the Former Chief Commercial Officer of Arrowhead Pharmaceuticals, Inc. I..
CI
08/10ARROWHEAD PHARMACEUTICALS : HC Wainwright Adjusts Arrowhead Pharmaceuticals' Price Target ..
MT
08/06ARROWHEAD PHARMACEUTICALS : Chardan Adjusts Price Target on Arrowhead Pharmaceuticals to $..
MT
More news
News in other languages on ARROWHEAD PHARMACEUTICALS, INC.
09/14VENTE D'INITIÉS : Arrowhead Pharmaceuticals
09/10VENTE D'INITIÉS : Arrowhead Pharmaceuticals
05/18Arrowhead obtient 10 millions de dollars de frais d'exercice d'option pour le produit c..
2018WALL STREET STOCK EXCHANGE : Les valeurs à suivre à Wall Street
2018Arrowhead conclut un accord avec J&J, son titre bondit
More news
Analyst Recommendations on ARROWHEAD PHARMACEUTICALS, INC.
More recommendations
Chart ARROWHEAD PHARMACEUTICALS, INC.
Duration : Period :
Arrowhead Pharmaceuticals, Inc. Technical Analysis Chart | ARWR | US04280A1007 | MarketScreener
Technical analysis trends ARROWHEAD PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 11
Last Close Price 66,16 $
Average target price 87,92 $
Spread / Average Target 32,9%
EPS Revisions
Managers and Directors
Christopher Richard Anzalone President, Chief Executive Officer & Director
Kenneth Allen Myszkowski Chief Financial Officer
Douglass B. Given Chairman
Javier San Martin Chief Medical Officer
Jeff Ketelhut Vice President-Information Technology & Systems
Sector and Competitors
1st jan.Capi. (M$)
ARROWHEAD PHARMACEUTICALS, INC.-13.78%6 898
GILEAD SCIENCES, INC.16.08%84 795
WUXI APPTEC CO., LTD.29.45%66 184
BIONTECH SE203.83%59 820
REGENERON PHARMACEUTICALS14.52%57 519
VERTEX PHARMACEUTICALS-23.09%47 156